MARKET

XERS

XERS

Xeris Biopharma Holdings
NASDAQ
7.01
+0.02
+0.29%
After Hours: 7.10 +0.09 +1.21% 18:53 12/18 EST
OPEN
7.10
PREV CLOSE
6.99
HIGH
7.21
LOW
6.99
VOLUME
1.96M
TURNOVER
--
52 WEEK HIGH
10.08
52 WEEK LOW
3.140
MARKET CAP
1.16B
P/E (TTM)
-67.7950
1D
5D
1M
3M
1Y
5Y
1D
Xeris Biopharma: A Balanced Perspective Needed (Rating Downgrade)
Seeking Alpha · 21h ago
Director Barbara-Jean Anne Bormann-Kennedy Sells Xeris Biopharma Holdings Inc. Common Shares
Reuters · 3d ago
Weekly Report: what happened at XERS last week (1208-1212)?
Weekly Report · 3d ago
Xeris Biopharma Initiated at Overweight by Barclays
Dow Jones · 12/09 16:38
Xeris Biopharma Price Target Announced at $9.00/Share by Barclays
Dow Jones · 12/09 16:38
Barclays Initiates Coverage On Xeris Biopharma Holdings with Overweight Rating, Announces Price Target of $9
Benzinga · 12/09 16:28
XERIS BIOPHARMA HOLDINGS INC. <XERS.O>:  BARCLAYS INITIATES COVERAGE WITH OVERWEIGHT RATING AND TARGET PRICE $9
Reuters · 12/09 11:33
Xeris Biopharma (XERS): Valuation Check After USPTO Notice of Allowance for Weekly Levothyroxine XP-8121 Patent
Simply Wall St · 12/09 11:11
More
About XERS
Xeris Biopharma Holdings, Inc. is a biopharmaceutical company focused on improving patient lives by developing and commercializing products across a range of therapies. It has three commercially available products: Recorlev, Gvoke, and Keveyis. Recorlev is for the treatment of endogenous Cushing’s syndrome. Gvoke is a ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is a therapy for primary periodic paralysis. It also has a pipeline of development programs led by XP-8121, a phase III-ready, once-weekly subcutaneous injection for hypothyroidism. It is pursuing formulation and development partnerships to apply its XeriSol and XeriJect formulation technologies to enhance the drug delivery and clinical profile of other companies’ proprietary drugs and biologics. Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adults with Cushing's syndrome for whom surgery is not an option or has not been curative.

Webull offers Xeris Biopharma Holdings Inc stock information, including NASDAQ: XERS real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XERS stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading XERS stock methods without spending real money on the virtual paper trading platform.